Nutraceutical Trial Targets Non-HDL Cholesterol in Polygenic Hypercholesterolaemia
A new randomized study is taking aim at a familiar problem in preventive cardiology: adults with polygenic hypercholesterolaemia whose lipid levels remain above target despite diet and lifestyle measures. The trial will compare a combined nutraceutical formulation, phytosterols alone, and placebo, with non-HDL cholesterol as the main endpoint after 6 weeks of blinded treatment.
The study is still recruiting and carries ClinicalTrials.gov identifier NCT07918677. It is being run in Bologna, Italy, through the Cardiovascular Internal Medicine Unit at IRCCS University Hospital of Bologna. The sponsor is ESI, and the protocol plans to enroll 60 adults.
The design is simple on paper and clinically pointed in practice: if a patient is at low to moderate estimated cardiovascular risk, has no diabetes, is not already on lipid-lowering drugs, and still carries an atherogenic lipid profile, can a nutraceutical strategy move the needle in a measurable way?
Why Non-HDL Cholesterol Was Chosen as the Main Endpoint
The protocol makes clear why non-HDL-C sits at the center of the trial. Unlike LDL cholesterol alone, non-HDL-C captures cholesterol contained in all apoB-containing lipoproteins, including remnant particles. In patients with mixed dyslipidaemia, that broader signal can better reflect total atherogenic burden.
The study population is limited to adults aged 18 to 75 years in primary prevention with an estimated 10-year cardiovascular risk below 10%. Entry criteria require either non-HDL cholesterol between 145 and 220 mg/dL or LDL cholesterol between 115 and 190 mg/dL. Triglycerides above 400 mg/dL exclude participation, as do diabetes, current lipid-lowering therapy, clinically significant hepatic or renal dysfunction, pregnancy, breastfeeding, and known intolerance to the study products.
That selection matters because it defines a group in which conventional drug treatment may not yet be indicated, deferred, or desired, even when the lipid profile remains stubbornly elevated. The trial is built around that gap in care.
Three Arms, One Blinded Phase, Then Open Label
The first 6 weeks are quadruple-masked, covering participants, care providers, investigators, and outcome assessors. During that phase, the study uses a parallel, three-arm format:
- placebo
- phytosterols alone
- combined dietary supplement, branded as Normolip® colesterolo
Each product is taken as two tablets once daily, preferably with a main meal. The placebo tablets are matched in appearance, packaging, and labeling to the active products.
One sentence in the protocol carries the practical weight of the design: the study is not only asking whether the combination beats placebo, but whether it does better than phytosterols alone.
The combined formulation is specified in detail. Each tablet contains 800 mg plant sterols, 170 mg bergamot dry extract standardized to 36% flavanones, corresponding to 61.2 mg naringin, and 50 mg artichoke dry extract standardized to 2.5% caffeoylquinic acids as chlorogenic acid, corresponding to 1.25 mg chlorogenic acid. Phytosterols alone are delivered as 800 mg per tablet.
After the blinded 6-week phase, all participants enter a 6-week open-label extension and receive the combined dietary supplement. That second phase extends follow-up to 12 weeks and offers a look at what happens when every participant is exposed to the same combination under less constrained conditions.
Lipid Biology and the Case for a Multi-Ingredient Approach
The biological rationale is straightforward. Plant sterols reduce intestinal cholesterol absorption, which has long made them a familiar nonprescription option in lipid management. Bergamot and artichoke extracts have each been proposed as complementary agents with possible effects on lipid metabolism, though the protocol does not claim definitive clinical superiority for either ingredient on its own.
What makes this study useful is its comparative structure. A common weakness in nutraceutical research is the absence of a clean comparator. Here, phytosterols alone serve as a credible active control, which creates a more informative test of whether the added botanical components provide incremental benefit rather than simply reproducing the known effect of sterol supplementation.
The investigators also plan secondary analyses across lipid fractions and selected inflammatory and liver-related indices, including hsCRP, RCII, LAP, HSI, and FLI. Those measures suggest an interest in whether the intervention influences not just cholesterol levels but also metabolic and inflammatory signals that travel alongside atherogenic dyslipidaemia.
What the Trial Can and Cannot Answer
This is a phase not applicable interventional study, so the focus is efficacy and biological signal, not drug approval or large-scale outcomes. The sample size is modest at 60 participants, which is appropriate for an early efficacy question but not for hard cardiovascular events. No results have been posted.
The exclusion criteria narrow the sample toward a relatively healthy primary-prevention population. That will help isolate lipid effects, but it also limits how far the findings can be generalized to older, sicker patients, people with diabetes, or those already treated with statins or other lipid-lowering agents.
The open-label extension adds another layer of interpretation. Once masking ends, expectations and adherence dynamics can change, so the 12-week data may be useful for describing real-world response patterns, but the cleanest causal inference will come from the initial 6-week blinded comparison.
A Focused Test in a Common Clinical Niche
Polygenic hypercholesterolaemia is common in practice because it sits between normal lipid variation and monogenic familial disease. Patients often look clinically well, their estimated short-term risk may be modest, and yet their atherogenic cholesterol burden remains persistently abnormal. That is the kind of case where clinicians frequently search for lower-intensity, well-tolerated adjuncts before escalating to long-term pharmacotherapy.
This trial is designed for exactly that niche. It asks whether a nutraceutical combination can outperform placebo and whether the added plant compounds contribute anything beyond sterols alone. The answer will matter most if the lipid changes are large enough to be clinically credible, durable over the open-label extension, and accompanied by tolerability that supports routine use.
For now, the study remains a structured hypothesis test in a carefully selected primary-prevention cohort. Its value will rest on whether the biochemical promise of phytosterols, bergamot, and artichoke translates into a measurable reduction in non-HDL cholesterol without sacrificing practicality at the bedside.